SYNDAX PHARMACEUTICALS INC
SNDXNASDAQTrading Snapshot
- Day Range
- $20.32 – $20.60
- 52-Week Range
- $12.10 – $25.59
- Volume
- $2.73B
- Avg Volume
- $2.21B
- Shares Outstanding
- 88.6M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $172M
- Last Q Revenue
- $73M
- P/E Ratio
- —
- P/S Ratio
- 7.2x
- EPS (TTM)
- $-2.52
- Dividend Yield
- —
Why Investors Own SNDX
- ✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SYNDAX PHARMACEUTICALS INC
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Syndax Pharmaceuticals, Inc.
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsSharon Klahre - Vice President of Investor Relations...
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates
Syndax Pharmaceuticals Q2 2026 revenue and EPS miss estimates, shares dip 6.5%; Revuforj sales up 91%, pipeline advances, cash position strong.
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 33.73 percent increase over losses of $(0.83) per